Response's troponin I and CK-MB POC heart tests:
This article was originally published in Clinica
Response Biomedical has received market clearance from Health Canada's Therapeutic Products Directorate to add two additional cardiac marker tests to its fluorescence-based, POC RAMP reader. The tests, for troponin I and CK-MB, are designed to help speed up heart attack diagnosis. The Vancouver, British Columbia firm has already gained Canadian approval to test for a third cardiac marker - myoglobin - on the RAMP reader and for the general clinical use of reader. The Reader and all three cardiac marker tests are already approved in the US, where, according to Response, the market for POC cardiac marker tests in 2004 is estimated to be around $150m.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.